安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2015年
9期
1791-1794
,共4页
复方丹参滴丸%糖尿病肾病%Meta分析
複方丹參滴汍%糖尿病腎病%Meta分析
복방단삼적환%당뇨병신병%Meta분석
compound danshen dropping pills%diabetic nephropathy%Meta analysis
目的:评价复方丹参滴丸治疗糖尿病肾病的疗效及安全性。方法计算机检索2006年9月至2014年9月,全面检索万方数据库、维普数据库、中国学术期刊全文数据库、中国生物医学文献数据库、Pubmed数据库,收集复方丹参滴丸治疗糖尿病肾病的试验,根据纳入和排除标准共纳入14项研究,1051例患者,选用空腹血糖、餐后2 h血糖、血肌酐、尿素氮、尿β2微球蛋白、尿微量白蛋白排泄率作为效应指标,使用RevMan5.0软件进行meta分析。结果(1)空腹血糖[WMD=-0.15,95%的CI为(-0.38,0.09),P=0.22],差异无显著性;餐后两小时血糖[WMD=-0.49,95%的CI为(-0.90,-0.08),P=0.02],差异具有统计学意义,治疗组均优于对照组(2)血肌酐[WMD=-1.74,95%的CI为(-5.40,1.92),P=0.35],差异无显著性;尿素氮[WMD=0.07,95%的CI为(-0.18,0.32),P=0.59],差异无显著性。(3)尿微量白蛋白排泄率[WMD=-11.95,95%的CI为(-16.27,-7.64),P<0.00001],差异具有统计学意义,治疗组均优于对照组。结论证据表明,复方丹参滴丸治疗糖尿病肾病疗效性、安全性较高。
目的:評價複方丹參滴汍治療糖尿病腎病的療效及安全性。方法計算機檢索2006年9月至2014年9月,全麵檢索萬方數據庫、維普數據庫、中國學術期刊全文數據庫、中國生物醫學文獻數據庫、Pubmed數據庫,收集複方丹參滴汍治療糖尿病腎病的試驗,根據納入和排除標準共納入14項研究,1051例患者,選用空腹血糖、餐後2 h血糖、血肌酐、尿素氮、尿β2微毬蛋白、尿微量白蛋白排洩率作為效應指標,使用RevMan5.0軟件進行meta分析。結果(1)空腹血糖[WMD=-0.15,95%的CI為(-0.38,0.09),P=0.22],差異無顯著性;餐後兩小時血糖[WMD=-0.49,95%的CI為(-0.90,-0.08),P=0.02],差異具有統計學意義,治療組均優于對照組(2)血肌酐[WMD=-1.74,95%的CI為(-5.40,1.92),P=0.35],差異無顯著性;尿素氮[WMD=0.07,95%的CI為(-0.18,0.32),P=0.59],差異無顯著性。(3)尿微量白蛋白排洩率[WMD=-11.95,95%的CI為(-16.27,-7.64),P<0.00001],差異具有統計學意義,治療組均優于對照組。結論證據錶明,複方丹參滴汍治療糖尿病腎病療效性、安全性較高。
목적:평개복방단삼적환치료당뇨병신병적료효급안전성。방법계산궤검색2006년9월지2014년9월,전면검색만방수거고、유보수거고、중국학술기간전문수거고、중국생물의학문헌수거고、Pubmed수거고,수집복방단삼적환치료당뇨병신병적시험,근거납입화배제표준공납입14항연구,1051례환자,선용공복혈당、찬후2 h혈당、혈기항、뇨소담、뇨β2미구단백、뇨미량백단백배설솔작위효응지표,사용RevMan5.0연건진행meta분석。결과(1)공복혈당[WMD=-0.15,95%적CI위(-0.38,0.09),P=0.22],차이무현저성;찬후량소시혈당[WMD=-0.49,95%적CI위(-0.90,-0.08),P=0.02],차이구유통계학의의,치료조균우우대조조(2)혈기항[WMD=-1.74,95%적CI위(-5.40,1.92),P=0.35],차이무현저성;뇨소담[WMD=0.07,95%적CI위(-0.18,0.32),P=0.59],차이무현저성。(3)뇨미량백단백배설솔[WMD=-11.95,95%적CI위(-16.27,-7.64),P<0.00001],차이구유통계학의의,치료조균우우대조조。결론증거표명,복방단삼적환치료당뇨병신병료효성、안전성교고。
Objective To evaluate the effect of compound danshen dropping pills to treat diabetic nephropathy,and safety.Methods computer retrieval from September 2006 to September 2014,comprehensive retrieve database,weipu database of ten thousand,China ac-ademic journal full-text database and Chinese biomedical literature database,Pubmed database,collection of compound danshen drop-ping pills in the treatment of diabetic nephropathy,according to include and exclude standards into 14 study,1 051 patients,choose Fasting plasma glucose,postprandial 2 hours blood glucose,serum creatinine,blood urea nitrogen,urine trace albumin excretion rate as an index of effect,use RevMan5.0 meta analysis software.Results (1)fasting glucose (WMD =-0.15,95%CI (-0.38,0.09), P =0.22),there was no significant difference;Two hours after meal the blood sugar (WMD =-0.49,95%CI (-0.90,-0.08), P =0.02),statistically significant difference,the treatment group were superior to control group.(2) serum creatinine (WMD =-1.74,95%CI (-5.40,1.92),P =0.35),there was no significant difference; blood urea nitrogen (WMD =0.07,95% CI (-0.18,0.32),P =0.59),there was no significant difference.(3) Urine trace albumin excretion rate (WMD = -11.95,95%CI (-16.27,-7.64),P <0.00001),statistically significant difference,the treatment group were superior to the control group.Con-clusion evidence that the compound danshen dropping pills in treatment of diabetic nephropathy curative effect,high safety.